December 1, 2025Journal of the American College of Cardiology1 citationsOpen Access
View Full PaperObesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition
Key Points
- Cardiovascular risk is increased in individuals with obesity and atherosclerotic cardiovascular disease, and evolocumab shows promise in mitigating this risk.
- The analysis indicates a meaningful impact of evolocumab on reducing major adverse cardiovascular events (MACE) associated with obesity.
- Assessment using clinical data highlights the benefit of PCSK9 inhibition in patients with elevated cardiovascular risk due to obesity and atherosclerosis.
- These findings suggest that pharmacotherapy targeting PCSK9 could enable better cardiovascular outcomes for obese individuals with heart disease.
Abstract
Individuals with obesity and atherosclerotic cardiovascular disease face an elevated risk of MACE compared with those without obesity, and evolocumab helps to attenuate this risk.